AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04500548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue samples
Study NCT04500548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT04500548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05655455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking group: 1.group
Description: In the study, walking attempt will be applied (2 x40 min/week and 6 weeks in total) to the 1st intervention group (n:15) in a gym. It will be given by a specialist in public health nursing. (first researcher)
Study NCT06547099 — intervention group
Intervention type: OTHER
Intervention: Cognitive assessments
Description: Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)
Study NCT05140421 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Data to Suppression (D2S)
Description: Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
Study NCT05212168 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-G1.1-NN
Description: Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
Study NCT05140421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data to Suppression (D2S)
Description: Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
Study NCT05212168 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Oral tablets similar in appearance and number to active vaccine tablets
Study NCT05212168 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Norovirus GI.1 Norwalk Virus Inoculum
Description: Norwalk Virus Inoculum Lot 01-09NV
Study NCT05212168 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Norovirus GI.1 Norwalk Virus Inoculum
Description: Norwalk Virus Inoculum Lot 01-09NV
Study NCT06017947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music care
Description: 20 min music listening during transportation to hospital
Study NCT05295368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Intervention includes four components 1) training nurses as health coaches for motivational conversation and CKD specific lifestyle counseling on diet and exercise, using hybrid follow-up approach of in-person, telephone, and secure video sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
Study NCT04149743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care with Hemotag
Description: Comparison of outcomes
Study NCT05495022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Description: Mindfulness-based stress reduction (MBSR) program will be applied by the researcher to the midwives in the experimental group. Conscious Awareness-Based Stress Reduction will be applied by the researcher (S.Ö.C.) who has received training (16 hours) and has a certificate in this field. Stress reduction program based on mindfulness is planned as 2 sessions per week for 4 weeks, a total of 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individual and group sessions by determining the days when midwives are available online.
Study NCT05655455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dance and movement therapy group: 2.group
Description: In the study, dance and movement therapy will be applied (2 x40 min/week and 6 weeks in total) to the 2nd intervention group (n:15) in a gym. It will be given by a specialist in psychiatric nursing.
Study NCT06001723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forest Therapy
Description: Forest healing activities are guided by professionals, allowing participants to engage in a two-hour sensory experience within the forest environment. This includes activities such as stacking leaves and stones, closing their eyes to listen to sounds, engaging in physical stretches, blindfolded tree identification, connecting with tree companions, creating earth mandalas, and partaking in tea ceremonies and sharing insights.
Study NCT04883944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Mother will be involved in implementing the non-pharmacological techniques during the performance of the heel stick procedure as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding;~* exposure to maternal voice.
Study NCT04883944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care group
Description: A second nurse will perform the non-pharmacological techniques during the performance of the heel stick procedure without the maternal involvement as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding.
Study NCT06547606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants in the control group will recieve usual care.
Study NCT06547606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control group will recieve usual care.
Study NCT05475821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-990
Description: Oral Tablet
Study NCT05818982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.
Study NCT05818982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
Study NCT05098002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness program
Description: 6 week class designed to improve psychological well-being
Study NCT04752488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR)
Description: The home exercise program will be educated to the patient on the first day. Exercises for isometric and isotonic strengthening, stretching, and stabilization of the neck muscles will be given. Exercises will be presented to the patients in audio-video format and detailed instructions with explanations. The exercise protocol will also be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
Study NCT04752488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation (CR)
Description: The home exercise program will be educated to the patient on the first day. Isometric and isotonic strengthening, stretching and stabilization exercises for the neck muscles will be given. Exercise information form including explanation and picture of the exercises will be given to the patients. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
Study NCT04858659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK101
Description: 1 tablet at each time, 2 times a day
Study NCT04858659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PK101-002
Description: 1 tablet at each time, 2 times a day
Study NCT04858659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PK101 placebo
Description: 1 tablet at each time, 2 times a day
Study NCT06159764 — intervention group
Intervention type: PROCEDURE
Intervention: Cardioneuroablation
Description: radiofrequency ablation to destroy cardiac ganglionated plexi located in epicardial fat pads around the atrias
Study NCT05475821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-990
Description: Oral Tablet
Study NCT06222021 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic analysis of polymorphism of membrane receptors involved in lactate transport
Description: The DNA extracted from the blood samples (through extractor MagCore) will then undergo gene sequencing by Sanger sequencing and/or Custom NGS (Next Generation Sequencing) panels and will be used to identify nucleotide variants within genes involved in lactate transport (MCT-1/4, GPR81).
Study NCT05358327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Study NCT05026086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure biofeedback
Description: 10 patients will be treated with isometric exercises and pressure biofeedback.
Study NCT05026086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isometric exercises
Description: 10 patients will be treated with isometric exercises
Study NCT05672797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellth app
Description: The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.
Study NCT05672797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit training
Description: Participants in treatment groups 1 and 2 will be asked to identify an existing routine behavior that will act as a cue for their daily pill-taking behavior to. However, only participants in treatment group 2 will have to submit visual evidence of their cue to the Wellth app in addition to photos of their medication in order to receive credit for the medication check-in (i.e., financial incentives conditional on using their cue).
Study NCT06532435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: DHA & ARA Candy
Description: Parpicipants need to eat 1-2 candy daily, for 4 consective weeks
Study NCT05892133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Description: 3 sessions/ week. leg press at \~85% of one repetition maximum for 8 weeks
Study NCT05923489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Routine Angiography Follow-up
Description: Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.
Study NCT05923489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine Clinical Follow-up
Description: Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
Study NCT05866835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manufacture of custom-made IOP
Description: Manufacture of custom-made unimaxillary and modified unimaxillary intra-oral protection (IOP) with vertical dimensions of 4 mm and 6 mm. 3D modeling of a IOP based on:~* digital recording of the maxillary and mandibular dental arches~* mandibular wedging performed with an inter-arch piece~* digital recording of the inter-arch position
Study NCT05866835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation tests
Description: Realization of a ventilation test (VO2max) to determine the Maximum Aerobic Speed (MAS).~Measurement of ventilatory parameters without IOP and with each IOP :~* At rest, standing still.~* During a 4 minute run on a treadmill at 50% of MAS.~* During a 4-minute run on a treadmill, at a speed corresponding to 70% of MAS
Study NCT05866835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of comfort level:
Description: Collection from participants (self-questionnaire)
Study NCT05126524 — intervention group
Intervention type: OTHER
Intervention: NO INTERVENTION
Description: Observational study, no intervention performed
Study NCT04950881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided vagus nerve block
Description: Before the operation starts, patients received the ultrasound guided vagus nerve block. A 50mm Braun nerve stimulation needle is guided by the ultrasonic beam to insert into the carotid sheath and 10ml of lidocaine or ropivacaine is injected.
Study NCT04950881 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bradycardia Treatment
Description: If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
Study NCT04950881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradycardia Treatment
Description: If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
Study NCT04858659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK101-002 placebo
Description: 1 tablet at each time, 2 times a day
Study NCT04486924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globe Mapping and Ablation System
Description: Prospective, non-randomized, open-label clinical study.
Study NCT05252884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: calcium correction according to PTH levels
Description: A PTH blood test will be performed 4 hours post-thyroidectomy. If the PTH result is >15 pg/mL, the patient will be discharged without calcium intake; if PTH \< 15 pg/mL, start a dose of 1200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days
Study NCT05252884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine postoperative calcium and calcitriol
Description: The patient will receive a dose of 1,200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days, starting on the same day as the intervention.
Study NCT06414460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM3412
Description: ISM3412 will be administered orally once daily.
Study NCT05127499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercises
Description: progressive relaxation exercises will do
Study NCT05016713 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine mouthwash is added to the oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.~If any participant shows any signs of CHX hypersensitivity, the intervention will be discontinued.
Study NCT06515769 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TERMOGRAPHY
Description: Obtaining an image of the foot using a thermographic camera
Study NCT05610462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Exercise Training Program
Description: The guided exercise program training consists of: a video demonstration, an exercise training session or group session, a follow up home visit, and virtual check-ins. The exercises include treadmill, wall sits, straight leg raise, bicep curls, hand grips with dynamometer at 40% maximal voluntary contraction (MVC), and Stationary cycling at moderate intensity (100 Watts).
Study NCT05610462 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care consists of routine clinic visits and standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
Study NCT04705727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Formoterol Drug Combination
Description: This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).
Study NCT04705727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulisation of terbutaline
Description: Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.
Study NCT05016713 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interdental brush
Description: Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
Study NCT05016713 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride-based toothpaste
Description: Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
Study NCT04829383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1,200 mg
Study NCT04829383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg
Study NCT05602259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: induced sputum
Description: After premedication with 400 μg inhaled salbutamol, sputum will be induced by inhalation of hypertonic (NaCl 3%) or isotonic (NaCl 0.9%) saline combined according to the FEV-1 value (> or ≤ than 65% predicted). Saline will be combined with additional salbutamol delivered by an ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9 ml/min. Each subject will inhale the aerosol for three consecutive periods of 5 min for a total of 15 min. For safety reasons, FEV-1 will be monitored throughout the induction and will be stopped if FEV-1 would fall by more than 20% from baseline.
Study NCT05602259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung biopsy
Description: As per standard practice, biopsies will be taken from the primary tumour site or from a metastatic site.
Study NCT05602259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchoalveolar lavage
Description: When available, the remaining material from a patient's bronchoalveolar lavage will be collected.
Study NCT05602259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood draw
Description: As per standard practice, blood will be drawn from patients before and during treatment. Data on white blood cells will be collected.
Study NCT06188052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Comparing the 3 groups regarding intraoperative bleeding, hemoglobin level pre and postoperative and the need of blood transfusion
Study NCT05016713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride-based toothpaste
Description: Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
Study NCT05726292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is being used in this study as an experimental drug combined with other treatments for prostate cancer.